Taking people in United StatesNo phase
Tracks how adults with schizophrenia feel about xanomeline and trospium treatment
Studies treatment preference and satisfaction in adults with schizophrenia taking xanomeline and trospium.
Key facts
- Who runs it
- Bristol-Myers Squibb
- Where
- Baltimore, Bel Air, Belle Mead, Belmont, Boston, Catonsville, El Paso, Evanston, Fort Mill, Grand Island, Kinston, Longview, Miami, New York, Omaha, Orange, Rose Hill, San Jose, South Dartmouth, and Westlake, United StatesSee the 20 sites
- Trial code
- Registry title
- Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 22 Sept 2025
- Expected to end
- 14 May 2029
- Type of study
- Observational
- Treatments tested
- xanomeline and trospium chloride (X/T) therapy
- Record updated
- 30 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with schizophrenia in the United States who have been prescribed xanomeline and trospium chloride (X/T) and plan to start it.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A confirmed diagnosis of schizophrenia before the start date
- Earlier treatment
- Must have a first prescription for xanomeline and trospium chloride (XT) and plan to fill and start it. Must not have used XT before screening.
Main reasons for not taking part
- Took part in an interventional study in the last 30 days
- Plans to take part in an interventional study at the time of screening
- Has already used XT before screening
- Cannot give signed written informed consent
- Does not speak English or Spanish
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Aged ≥18 years at index date
- Have a confirmed diagnosis of schizophrenia before index date
- Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy
- Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines
- Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish)
- English or Spanish speaking
Who cannot take part
- Evidence of use of XT prior to time of eligibility screening
- Participation in an interventional study within the last 30 days or plan to participate in such study at the time of eligibility screening
Where in United States
- The Johns Hopkins HospitalBaltimore, United StatesContact: Frederick Nucifora, Site 0007Taking people
- Bel Air, MarylandHospital not named in the registryNo longer taking part
- Hackensack Meridian Health - Carrier ClinicBelle Mead, United StatesContact: Stacy Doumas, Site 0001Taking people
- Belmont, MassachusettsHospital not named in the registryNo longer taking part
- Boston Medical CenterBoston, United StatesContact: Hannah Brown, Site 0002Taking people
- Catonsville, MarylandHospital not named in the registryNo longer taking part
- Haracec Clinical ResearchEl Paso, United StatesContact: Aghaegbulam Uga, Site 0012Taking people
- Evanston HospitalEvanston, United StatesContact: Joshua Straus, Site 0003Taking people
- Continuum Health ProvidersFort Mill, United StatesContact: Brian Mika, Site 0006Taking people
- Grand Island, NebraskaHospital not named in the registryContact: Site 0020Not yet recruiting
- New Dawn Psychiatric Services, PLLCKinston, United StatesContact: Punitha Rathnam, Site 0016Taking people
- C-Trilogy OutreachLongview, United StatesContact: Tracy Hicks, Site 0013Taking people
- Miami, FloridaHospital not named in the registryContact: Site 0019Not yet recruiting
- Radial - ManhattanNew York, United StatesContact: Owen Muir, Site 0015Taking people
- Omaha Insomnia and Psychiatric ServicesOmaha, United StatesContact: Vithya Selvaraj, Site 0005Taking people
- ATP Clinical Research - Costa MesaOrange, United StatesContact: Gustavo Alva, Site 0009Taking people
- New Dimension GroupRose Hill, United StatesContact: Constance Olatidoye, Site 0018Taking people
- Lumos Clinical Research CenterSan Jose, United StatesContact: Sarbani Maitra, Site 0010Taking people
- South Dartmouth, MassachusettsHospital not named in the registryNo longer taking part
- Westlake Brain HealthWestlake, United StatesContact: Abdelrahman Abdelaziz, Site 0014Taking people
About the trial
What the trial wants to find out
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
The group in the trial
- Participants receiving xanomeline and trospium chloride (X/T) therapy
Treatment: xanomeline and trospium chloride (X/T) therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
- Plain-language title
- Tracks how adults with schizophrenia feel about xanomeline and trospium treatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 September 2026